We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalBurzynski Research Institute (BZYR)

Previous 10 
To: paul j. gourley who wrote (10)12/14/1997 11:03:00 PM
From: mike head
   of 15
OK, Paul, here it is (I hope)

ÿ Tell Me More - From Infoseek

Burzynski Research Institute Advances Clinical Trials for New Cancer Treatment and Completes New SEC Filing

December 10, 1997 11:26 AM EST

HOUSTON--(BUSINESS WIRE)--Dec. 10, 1997--Burzynski Research Institute Inc. (OTC Bulletin Board: BZYR) has filed a Form 10SB with the Securities and Exchange Commission which will make it a reporting company and allow the Company's stock to be marketed and supported by NASD broker/dealers.

Additionally, the Company announced a new clinical trial earlier this year for its experimental drugs, ANTINEOPLASTONS, for the treatment of liver cancer. Currently, Burzynski Research Institute is sponsoring a total of 72 Phase II Clinical Trials of ANTINEOPLASTONS in the treatment of a variety of cancer types and advanced stages. Early clinical results indicate particular promise with malignant brain tumors and lymphomas.

An interim analysis of three clinical studies indicates that from 33% to 50% of evaluable brain tumor patients accomplished either complete tumor elimination or reduction of tumor size by more than 50%.

ANTINEOPLASTONS are peptides, amino acid derivatives and certain organic acids that occur naturally in healthy individuals and, according to CEO and founder, Stanislaw R. Burzynski, M.D., Ph.D., may constitute the body's first and most effective line of defense against cancer.

The Company plans to submit the results of its current clinical trials to the FDA in January, 1998. If FDA finds the results of the trials sufficiently promising, Burzynski Research Institute Inc. will initiate a procedure to generate data which will support a New Drug Application (NDA).

Burzynski Research Institute stock is publicly traded on the OTC. Earlier this year, BRI retained the services of Brewer-Gruenert Capital Advisors, L.L.C., in Houston, to guide the Company in preparing for expected growth based upon its expectations of the positive results of the latest round of clinical trials.

c Business Wire. All rights reserved.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: mike head who wrote (11)12/16/1997 10:43:00 PM
From: bebu
   of 15
Hello Mike & Paul:
here's the site for BZYR.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: bebu who wrote (12)12/18/1997 1:16:00 AM
From: paul j. gourley
   of 15
Hi Everybody, I tried to call the company today. Left a message, hopefully they will call me back. If not I'llpay them a visit since I live and work in the Houston vicinity. I wanted to find out exactly what the capital advisors were going to do for the company. I also wanted to find out shares outstanding. I also called both people whom were mentioned on press release, voice mail both times, no return phone calls. I will try to keep you all posted. See ya! Paul G. in Houston.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: paul j. gourley who wrote (13)2/11/1998 1:29:00 PM
From: bebu
   of 15
7:45 PM 2/10/1998

Burzynski agrees not to distribute cancer drug in Texas
Copyright 1998 Houston Chronicle Medical Writer

The Texas Attorney General's office and a controversial Houston physician formally agreed Tuesday that the doctor will not distribute his unapproved cancer drug in the state or treat patients who are not in a federally approved study.

However, it is unlikely the accord will limit Dr. Stanislaw Burzynski's use of the medicine antineoplastons.

Robert Reyna, chief of the Dallas consumer protection office for the attorney general, and Richard Jaffe, Burzynski's lawyer, said the court agreement will have little effect because most of the doctor's patients are in one of 72 studies approved by the U.S. Food and Drug Administration.

Burzynski has agreed to pay $50,000 to the Texas Attorney General's office and the Texas Department of Health to reimburse the agencies for attorneys' fees and the costs of investigations, Reyna said.

The agreement stipulates that Burzynski:

ú Refrain from distributing his unapproved drug antineoplastons in Texas.

ú Use antineoplastons only to treat people enrolled in one of his 72 clinical trials being conducted with the approval of the U.S. Food and Drug Administration.

ú Not advertise antineoplastons cancer treatment.

úPlace a disclaimer on his Web site and other material stating that the safety and effectiveness of antineoplastons have not been established.

Burzynski now practices under a 10-year probationary order from the Texas State Board of Medical Examiners. Those requirements are similar to the agreement with the attorney general.

He had appealed the state board's order, but he lost his case last year before the Texas Supreme Court.

By signing the agreement with the attorney general, Burzynski admitted that the drug never had been legally sold in Texas, Reyna said.

The medical board will monitor Burzynski's practice and investigate any patient complaints, said Reyna.

The attorney general's office will monitor use of antineoplastons in Texas.

Jaffe said he is satisfied with the agreement. "It is the first time since 1983 that Burzynski has been without pending state or federal action against him," Jaffe said.

Burzynski began using antineoplastons in the late 1970s. At that time, the drug was not approved for study or use by the FDA.

Texas officials did not take action against Burzynski at that time, saying he could do what he wished in his own practice.

But in 1983, a federal judge in Houston told Burzynski he could not send the drug across state lines.

In 1991, the National Cancer Institute agreed to oversee studies of antineoplastons at institutions unrelated to Burzynski.

However, few patients enrolled in the studies that began in 1993. They were ended in 1995 when the NCI and the physician could not agree on how to change patient qualifications so that more people could participate.

In 1995, Burzynski was indicted on federal fraud charges related to use of the drug, but some charges were dismissed by the federal judge in the case. Juror were deadlocked on the remaining counts.

Subsequently, government prosecutors dropped all but one remaining charge against Burzynski. In May, the doctor was acquitted on that count of violating a 1983 federal court order prohibiting him from sending his drug across state lines.

In 1996, the FDA approved at least 60 new clinical trials of antineoplastons to be run by Burzynski and the Burzynski Research Institute.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)

To: bebu who wrote (14)3/3/1998 3:47:00 AM
From: Trey McAtee
   of 15

just curious, but is this burzynski guy for real?

tonight i have been reading a lot about vitamin b17, and all matter of odd therapies. while i am not adverse to them ( i mean the doctors say that green leafy vegetables will fight cancer, why not apricot seeds) i simply am a little doubtful based on the incredible amount of anti-alternative treatment information that seems to pour from the mouth of every doctor.

there is also a personal element. one of my aunts is currently being treated for non-hodgkins lymphoma, and my other aunts husband (who just happens to be a doctor, big suprise) says this stuff is nonsense.

anyway, TIA, and good luck to all,

Share RecommendKeepReplyMark as Last Read
Previous 10